Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 182 participants.
Also called NCT03532009
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 182 participants
- Sponsor
- Registry
-
NCT03532009
-
- Other papers using this trial's data
- Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Brazil, Bulgaria, Canada, Hungary, Poland, Romania, Russia, Slovakia
- Registry status
- Terminated
Technical summary
Registry record NCT03532009. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-26 (actual); primary completion 2020-05-22 (actual). Results posted on 2021-06-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
- Acronym
- PRIORITIZE HF
- Condition
- Heart Failure
- Intervention (Drug)
- Sodium Zirconium Cyclosilicate
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct03532009- Content hash
fd3f6982984b973502cd87ab4ee6337c1c570d734b42c31e546b7d48106ee2f6